A new generation of vaccines within animal health
Together with our two subsidiaries Nordvacc Läkemedel and the Mybac-Vettech Laboratory, we strive to strengthen animal health and welfare. Here you can find more about the Group’s products and services and our vaccine candidate against equine strangles, Strangvac ®, the first of the new generation of vaccines.
- Intervacc’s subsidiary company Nordvacc have over 30 years’ experience in the veterinary vaccines market, serving the Nordic, Dutch and Baltic markets with more than 150 million doses sold
- The technology platform is based on research from the Karolinska Institute and the Swedish University of Agricultural Sciences
Interview with Intervacc´s CEO, Jan-Ingmar Flock
In this video interview Intervacc CEO Jan-Ingmar Flock answers questions about the company and the first vaccine candidate, Strangvac® against Strangles – a highly contagious, equine plague affecting horses.
The interview is avalible in Swedish only.